Welcome to our dedicated page for Edgewise Therapeutics SEC filings (Ticker: EWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edgewise Therapeutics, Inc. filings document a late-stage clinical biopharmaceutical company developing treatments for severe muscle diseases, including programs for muscular dystrophies and serious cardiac conditions. Form 8-K reports furnish quarterly and annual financial results, Regulation FD clinical-program disclosures, and material governance events.
The company’s proxy materials describe board structure, director elections, executive compensation, equity-award information, stockholder voting matters, and governance practices. Other disclosed matters include officer appointments, director appointments, compensatory arrangements, exhibits to earnings releases, and operating context for a development-stage drug pipeline.
Edgewise Therapeutics, Inc. disclosure: Janus Henderson Group plc reported beneficial ownership of 5,915,556 shares of common stock, representing 5.5% of the class as of 03/31/2026. The filing states the Asset Managers exercise shared voting and dispositive power over these shares on behalf of Managed Portfolios. The Asset Managers disclaim rights to receive dividends or sale proceeds; the Managed Portfolios themselves have the rights to dividends and proceeds and, according to the filing, no single Managed Portfolio owns more than 5%.
Edgewise Therapeutics reported first quarter 2026 results highlighted by continued investment in its muscle and cardiovascular pipeline and a larger loss. Net loss was $49.0 million, or $0.46 per share, compared with $40.8 million, or $0.43 per share, a year earlier.
Research and development expenses rose to $42.7 million from $36.8 million, and general and administrative expenses increased to $11.5 million from $9.2 million. The company ended March 31, 2026 with $499.6 million in cash, cash equivalents and marketable securities. Edgewise also reported positive long-term sevasemten data in Becker muscular dystrophy and reiterated key upcoming readouts, including GRAND CANYON pivotal data in Becker in the fourth quarter of 2026 and 12-week CIRRUS-HCM data in hypertrophic cardiomyopathy in the second quarter of 2026.
Edgewise Therapeutics reported a net loss of $49.0 million for the three months ended March 31, 2026, as it continued investing heavily in late-stage clinical programs for severe muscle and cardiac diseases. Research and development expenses rose to $42.7 million, with spending focused on sevasemten, EDG-7500, EDG-15400 and discovery work.
The company held $499.6 million in cash, cash equivalents and marketable securities as of March 31, 2026 and believes this will fund operations for at least 12 months. Total assets were $518.5 million and stockholders’ equity was $493.2 million, reflecting a development-stage profile with an accumulated deficit of $595.4 million and no product revenue yet.
Insider sale notice: A Form 144 reports a proposed sale of 50,000 shares of Common Stock related to an exercise of stock options, dated 05/05/2026, with cash proceeds specified. The filing also lists recent Rule 10b5-1 sales totaling 71,588 shares across March–May 2026.
Edgewise Therapeutics, Inc. CMO Joanne M. Donovan reported an option exercise and related stock sales. On May 5, 2026, she exercised stock options to acquire 50,000 shares of common stock at $7.08 per share, then sold 50,000 shares at an average price of $38.568.
On May 4, 2026, she also sold 5,230 shares at an average price of $31.2931. The filing notes both sales were made in multiple transactions within disclosed price ranges and were effected under a Rule 10b5-1 Plan adopted on December 26, 2025. Following these transactions, she directly holds 4,367 shares of Edgewise Therapeutics common stock.
Novo Holdings A/S filed Amendment No. 6 to its Schedule 13D on Edgewise Therapeutics, Inc., reporting that its ownership has been diluted below five percent of the company’s common stock.
Novo Holdings beneficially owns 5,350,000 shares of common stock, representing approximately 4.98% of Edgewise’s outstanding shares, based on 107,532,173 shares outstanding as of April 9, 2026. The filing states this change results from dilution rather than any purchase or sale of shares, and confirms no transactions in the stock by Novo Holdings or related parties within the past 60 days.
Edgewise Therapeutics, Inc. is asking stockholders to vote at its in‑person annual meeting on June 4, 2026 in Boulder, Colorado. Stockholders of record as of April 9, 2026 may vote by internet, phone, mail or in person.
The board recommends voting for three Class II directors – Laura Brege, Badreddin Edris, Ph.D., and Jonathan Root, M.D. – for terms running until the 2029 annual meeting. It also recommends ratifying KPMG LLP as independent auditor for the year ending December 31, 2026 and approving, on an advisory basis, the compensation of the company’s named executive officers.
The proxy describes a largely independent, staggered board structure, outlines committee memberships, and details a non‑employee director compensation program with cash retainers and equity awards, including higher retainers and equity grant values effective April 1, 2026. It also highlights governance policies such as an Insider Trading Policy, hedging prohibitions and a Compensation Recovery Policy.
Edgewise Therapeutics, Inc. director Jonathan C. Fox received a grant of 339 shares of Common Stock as a stock award. The shares were acquired at no cash cost to him and increase his direct ownership to 24,514 shares following the transaction on April 1, 2026.
Edgewise Therapeutics, Inc. Chief Medical Officer Joanne M. Donovan reported an option exercise and related share sale. On April 1, 2026, she exercised stock options to acquire 28,662 shares of common stock at $7.08 per share, then sold 28,662 shares of common stock at an average price of $32.3109 per share. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025. After these transactions, she directly holds 9,597 shares of Edgewise Therapeutics common stock.